Results from a phase III clinical trial conducted in Germany suggest that the standard initial treatment for patients with slow developing (or indolent) types of B-cell lymphoma should be changed.
The trial's lead investigator, Dr. Mathias Rummel of the University Hospital in Giessen, Germany, reported that patients treated with a combination of rituximab (Rituxan) and bendamustine (Treanda) lived significantly longer without their disease progressing and were less likely to experience major toxicities than patients treated with the standard first-line treatment, a four-drug chemotherapy regimen plus the monoclonal antibody rituximab called R-CHOP. Read more > >
Declines continue. When it comes to cancer rates, those two words are always encouraging. In fact, they were the headline attached to most news stories last week reporting the release of the 2009 Report to the Nation on the Status of Cancer. Understanding that this is not just a single year's trend, as the report made clear, but that many cancer rates have been on the decline for more than a decade, is particularly encouraging. Read more > >
The president of the American Cancer Society shares his thoughts about past accomplishments and future efforts in cancer research Read more > >
- Fred Hutchinson Cancer Research Center to Operate NCI's CIS Contact Center
- Application Deadlines Approach for Interagency Oncology Task Force Fellowships
- President's Cancer Panel Examines Race and Cancer Burden
A MESSAGE TO READERS
NCI Cancer Bulletin Publication Break
The NCI Cancer Bulletin will not be published on December 29. However, subscribers will receive via e-mail a list of the 10 most viewed articles from recent months. Our next issue will be released on January 12, when we resume our usual biweekly publication schedule. If you are not yet a subscriber, submit your e-mail address in the subscribe box above.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at firstname.lastname@example.org.